Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
RECORD analysis shows cardiovascular safety of Avandia
Avandia :: RECORD analysis shows cardiovascular safety of Avandia
GlaxoSmithKline [NYSE:GSK] said that findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), a prospective clinical trial designed specifically to determine cardiovascular outcomes in more than 4,400 patients with type 2 diabetes, adds further evidence to the overall cardiovascular safety profile of Avandia? (rosiglitazone maleate).The study compares cardiovascular hospitalization and death in patients treated with Avandia dual therapy (Avandia plus metformin or sulfonylurea) and in patients treated with metformin and sulfonylurea in combination. After following patients for an average of 3.75 years, the interim analysis found a low number of events overall, and a similar number of events in each group. The study is scheduled to complete in late 2008.
Like all interim analyses, these data do not offer final conclusions. Based on the interim analysis, key findings include:
The interim data show no significant difference between the Avandia and control groups in the key outcomes of hospitalization or death due to cardiovascular events.
There was no difference between the groups in mortality, whether cardiovascular deaths or deaths from all causes.
The interim data show that Avandia was not significantly different than the control groups in several secondary outcomes, including heart attack.
A significant difference between the Avandia and control groups was seen only in the secondary outcome of congestive heart failure (CHF), where significantly more cases were seen in Avandia patients ? consistent with the well known association between fluid retention and TZDs, the class of medicine to which Avandia belongs. Fluid retention can worsen or lead to CHF. Importantly, despite the increase in CHF, there was no difference between the Avandia group and the control groups in the key outcome of cardiovascular hospitalizations and death.
?The interim findings do not show evidence of a significant difference in cardiovascular death and heart attack between Avandia and the control groups, and therefore do not confirm the hypothesis generated by the recently published meta-analysis in the New England Journal of Medicine that raised concerns about these events with Avandia,? said Moncef Slaoui, chairman, R&D for GSK. ?They addto the weight of evidence, from both previously published long-term clinical trials and other studies, that the overall ischemic cardiovascular safety profile of Avandia is comparable to the traditional anti-diabetes treatments. Patients and physicians should find these data reassuring.?
Because Avandia has been shown to control blood sugar for longer than other traditional oral anti-diabetic medicines, it is an important option for physicians who often need to prescribe a combination of diabetes medicines to help their patients maintain blood sugar levels.
(Avandia :: RECORD analysis shows cardiovascular safety of Avandia published at SpiritIndia on Wednesday, June 6, 2007)
Avandia
Search more information on Avandia, Avandia booksRecently posted related articles on Avandia :
- Diabetes :: European Medicine Agency confirms positive Avandia benefit risk assessment
- Diabetes :: JAMA articles do not confirm difference in safety of Avandia and Actos, says GSK
- Avandia :: Glaxo updates prescribing information for Avandia in US
- Avandia :: Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
- Avandia :: Keep GSK diabetes drug Avandia available to US patients
- Avandia :: FDA Advisory Panel supports Glaxo's diabetes drug Avandia
- Avandia :: GlaxoSmithKline presents Avandia data to FDA
- Diabetes :: New review adds more reasons to avoid diabetes drug Avandia
- Avandia :: Newly published data from large study support cardiovascular safety of Avandia
- Avandia :: RECORD analysis shows cardiovascular safety of Avandia
Most related articles:
- Avandia :: RECORD analysis shows cardiovascular safety of Avandia- Avandia :: GlaxoSmithKline presents Avandia data to FDA - 19.8
- Diabetes :: GlaxoSmithKline strongly defends its record on Avandia - 19.4
- Avandia :: Data affirms Avandia cardiovascular safety profile - 19.4
- Avandia :: Newly published data from large study support cardiovascular safety of Avandia - 17.7
- Diabetes :: FDA has requested black box warnings for two diabetes medications - 17.1
- Avandia :: GlaxoSmithKline response to New England Journal of Medicine Editorials - 16.8
- Avandia :: FDA Advisory Panel supports Glaxo's diabetes drug Avandia - 16
- Avandia :: Keep GSK diabetes drug Avandia available to US patients - 15.2
- Avandia :: Glaxo updates prescribing information for Avandia in US - 14.9
»» Childhood Obesity :: Obesity risk more for children of overweight or single parents
«« Doping :: Growth hormone does not improve sports performance or increase muscle
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com